Back to today’s briefing

Story perspectives

AbbVie Near $10.9B Apogee Deal, Secures Blood-Cancer Approval

6/20/2026

44 4 Full Breakdown

Summary

Story summary

AbbVie is near a $10.9 billion cash acquisition of Apogee Therapeutics.
The deal values Apogee at a 60% premium, a market cap of $6.81 billion, and a 19.7% YTD share rise.
Apogee secured up to $1.3 billion from Blackstone Life Sciences for late-stage development of its lead eczema drug.
AbbVie also won FDA approval for pivekimab sunirine-pvzy, a rare blood-cancer treatment, after its U.S. offices closed on Juneteenth.

1 of 1

Story summary

AbbVie is near a $10.9 billion cash acquisition of Apogee Therapeutics.
The deal values Apogee at a 60% premium, a market cap of $6.81 billion, and a 19.7% YTD share rise.
Apogee secured up to $1.3 billion from Blackstone Life Sciences for late-stage development of its lead eczema drug.
AbbVie also won FDA approval for pivekimab sunirine-pvzy, a rare blood-cancer treatment, after its U.S. offices closed on Juneteenth.